Additionally, Unity Biotechnology also announced 3 Yehia Hashad, MD, executive vice president of research and development and ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

On March 5, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s entry ...

AVT06 is an aflibercept biosimilar candidate for the treatment of eye disorders such as neovascular (wet) age-related macular degeneration (AMD), macular edema, and diabetic retinopathy.

aflibercept, according to study data. Patients with DME and neovascular AMD who were treated with faricimab demonstrated noninferior vision gains and improved anatomical outcomes vs. those treated ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...